This book provides a comprehensive overview of the development of therapeutic oligonucleotides for therapeutic applications, touching on a number of additional oligonucleotides including a number of small interfering RNAs currently in various phases of clinical development. Written by leading expert scientists from both academia and leading biotechnical companies, the authors provide a compelling update on current status of RNA interference with emphasis on fascinating topics including oligonucleotides: antisense oligonucleotides, ribozymes, siRNAs, decoy oligonucleotides and aptamers. This exceptional work will be a valid resource for researchers and students as well as academia, consultants and scientists.

Chapter 1: The Role of Backbone Modifications in Oligonucleotide-Based Strategies; Chapter 2: Genasense (G3139): An Antisense Bcl-2 Oligodeoxyribonucleotide with Substantial Clinical Activity and a Complex Mechanism of Action; Chapter 3: Antisense Morpholino Oligomers and Their Peptide Conjugates; Chapter 4: Peptide-PNA Conjugates for Modulation of Gene Expression; Chapter 5: Locked Nucleic Acid: Properties & Therapeutic Aspects; Chapter 6: Immune Stimulatory Oligonucleotides; Chapter 7: Decoy Oligonucleotides to Treat Inflammatory Diseases; Chapter 8: AS1411: Development of an Anticancer Aptamer; Chapter 9: Spielgelmer NOX-E36 for Renal Diseases; Chapter 10: Strategies for the Delivery of Oligonucleotides In Vivo; Chapter 11: Lipid-Mediated in vivo Delivery of Small Interfering RNAs; Chapter 12: Vector-Mediated and Viral Delivery of Short Hairpin RNAs; Chapter 13: Development of an RNAi Based Gene Therapy against HIV-1; Chapter 14: RNA Based Therapies for Treatment of HIV Infection